Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV5-hRKp.RPGR Second Eye Treatment in X-linked Retinitis Pigmentosa
NCT06646289Phase 2Active, not recruiting
- Sponsor
- MeiraGTx
- Start
- Oct 2024
- Primary completion
- Oct 2030
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP), sponsored by MeiraGTx. Started Oct 2024; status: active, not recruiting.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on NCT06646289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646289.